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Introduction
Migraine headache is a common presenting complaint to
the emergency department (ED). Aims of treatment
include rapid pain relief, improvement in associated
symptoms, minimisation of length of stay and prevention
of recurrence. Many treatment alternatives have been
shown to be effective in the treatment of acute migraine
attack including non-steroidal anti-inflammatory drugs
(NSAID), antiemetics, phenothiazines, narcotics, ergot
alkaloids and triptans [1–9].
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Abstract The aim of this prospec-
tive, randomised, double-blind study
was to evaluate the efficacy of intra-
muscular (IM) tramadol 100 mg in
emergency department treatment of
acute migraine attack and to com-
pare it with that of IM diclofenac
sodium 75 mg. Forty patients who
were admitted to our emergency
department with acute migraine
attack according to the International
Headache Society criteria were
included in the study. Patients were
randomised to receive either tra-
madol 100 mg (n=20) or diclofenac
sodium 75 mg (n=20) intramuscular-
ly. Patients rated their pain on a
four-point verbal scale (0=none,
1=mild, 2=moderate, 3=severe) at
the beginning of the trial and at 30,
60, 90 and 120 min. At each time
interval, severity of associated
symptoms were also questioned and
recorded. Global evaluation of the
drugs by patients and doctors were
also recorded. Patients were also
asked if they would prefer the same
injection in future visits. Any
adverse events, whether related to
the drug or not, were also recorded.
Patients were followed up by tele-
phone 48 h later to check for any
headache recurrence. Two-hour pain
response rate, which was the prima-
ry endpoint, was 80% for both tra-
madol and diclofenac groups. There
were no statistically significant dif-
ferences among groups in terms of
48-h pain response, rescue treat-
ment, associated symptoms’
response, headache recurrence and
adverse event rates. Fifteen (75%)
patients in the tramadol group and
16 (80%) patients in the diclofenac
group stated that they may prefer the
same agent for future admissions. In
selected patients, tramadol 100 mg
IM may be an effective and reliable
alternative treatment choice in acute
migraine attacks.
Key words Migraine treatment •
Tramadol • Diclofenac •
Randomised controlled trial
Received: 6 February 2005
Accepted in revised form: 15 April 2005
Published online: 13 May 2005
144
Although it is not the recommended first-line therapy,
in nearly half of migraine headaches emergency physi-
cians in the USA prefer parenteral opioids [10]. Tramadol
is an opioid agent with central activity. Mechanism of its
analgesic activity involves two components: low-affinity
binding to opioid receptors and inhibition of monoamine
reuptake [11]. Tramadol has a proven analgesic activity
for many acute and chronic pain conditions [12–16].
Adverse effects, nausea in particular, are dose-dependent
and therefore considerably more likely to appear if the
loading dose is high. Other adverse effects are similar to
those of other opioids but they appear to be less severe
[11]. Potential dependence, tolerance and abuse rates of
tramadol are also reported to be relatively low [17]. With
these features tramadol appears to have a potential role in
the treatment of headaches. However, there is limited data
on its use in headache [10, 18] and we could not find any
study on its use in acute migraine attack.
The aim of this study was to evaluate the efficacy of
intramuscular (IM) tramadol 100 mg in ED treatment of
acute migraine attack and to compare it with that of IM
diclofenac sodium 75 mg, an agent shown to be effective
in treatment of acute migraine attacks [1–4], in a prospec-
tive, randomised and double-blind fashion. The primary
outcome measure of the study was 2-h pain response after
the injection of the study drug. A sample size of 32
patients was determined to achieve 80% power to detect
an effect size of 0.5 using a 1 degree of freedom Chi-
Square Test with a significance level (alpha) of 0.05.
Methods
This prospective, randomised, double-blind trial was conducted
in a university hospital ED with an annual census of about
26 000. The study was designed according to the second edition
of guidelines for controlled trials of drugs in migraine [19]. The
institutional review board and ethics committee approved the
study (Decision number: 2003-24-03). Informed consent of all
eligible patients was obtained before the study. The study was
performed in accordance with the ethical standards of the 1964
Declaration of Helsinki.
All patients between 18 and 65 years of age with acute
migraine attack according to the second edition of the
International Headache Society (IHS) criteria for migraine with-
out aura [20] were eligible. Patients with any known sensitivity
to either tramadol or diclofenac, patients taking excessive anal-
gesics (more than 10 days per month), patients using antidepres-
sants and antipsychotics regularly within the last 3 months,
patients with history of epilepsy, alcohol or drug abuse, patients
over 50 years of age with new onset migraine and pregnant or
lactating patients were excluded from the study.
Patients with other types of headache (e.g., tension-type
headache) together with migraine were included in the study if
they could clearly differentiate the type of headache. Patients
who had taken analgesics or anti-migraine medication prior to
ED admission were included only if there was no response to
drug and if more than 6 h had passed between use of the drug and
ED admission. Regular prophylactic migraine medications, other
than antidepressants and antipsychotics (as they may interact
with central nervous system effects of tramadol), were allowed.
Patients were allowed to participate in the study only once.
After a detailed headache history, a general physical and
neurological examination was performed in all eligible patients
by the attending emergency physician. Diagnosis and eligibility
for the study were then confirmed by a neurologist. Baseline
headache characteristics and presence or absence of associated
symptoms (nausea, vomiting, photophobia and phonophobia)
were recorded. Severity of the headache was rated on a four-
point verbal scale (0=none, 1=mild, 2=moderate, 3=severe) [19].
After the collection of baseline data, patients were ran-
domised to receive either tramadol 100 mg IM or diclofenac
sodium 75 mg IM. Randomisation was achieved by computer-
based generation of random numbers. To assure blindness, tra-
madol preparation, which was 2 ml, was completed to 3 ml with
normal saline solution to look identical to diclofenac sodium 75
mg 3 ml preparation. Injections were prepared and applied by a
nurse who was not a part of the study. Neither the patient nor the
physician was allowed to learn the contents of the injection until
the end of the study period.
After the injection, patients rated the severity of pain on the
four-point verbal scale at 30, 60, 90 and 120 min. At the end of
the study period (2 h), the presence or absence of associated
symptoms was recorded. Patients were questioned about whether
or not they would prefer the same injection for future admissions.
Any adverse events that could be related or not related to the drug
were also recorded. Patients and doctors globally evaluated the
drug on a 5-point verbal scale (0=very poor, 1=poor, 2=no opin-
ion, 3=good, 4=very good). After these data were obtained the
doctor and the patient were informed of the content of the injec-
tion. Then, the patients with a pain score of 2 (moderate) or 3
(severe) or with unbearable associated symptoms received rescue
treatment at the discretion of the emergency physician. Patients
were followed up by telephone 48 h after the ED admission and
questioned about any headache recurrence, use of additional anal-
gesics and any search for medical assistance.
The primary outcome measure of the study was 2-h pain
response and positive response was defined as pain score
dropping from 3 or 2 to 1 or 0 within 2 h after the injection.
Secondary outcome measures were 2-h pain-free response,
48-h pain response, 48-h pain-free response, response to associ-
ated symptoms, rescue treatment, recurrence and adverse event
rates. Two-hour pain-free response was defined as pain score
dropping from 3 or 2 to 0 within 2 h. Positive 48-h pain
response was defined as patients with a positive 2-h pain
response without rescue treatment and recurrence at 48-h fol-
low-up. Positive 48-h pain-free response was defined as
patients with a positive 2-h pain-free response without rescue
treatment and recurrence at 48-h follow-up. Response to associ-
ated symptoms was accepted as positive if the symptom
improved or was completely relieved.
All demographic, baseline, study and follow-up data were
recorded on a standard study form by a resident or attending
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physician. Data was then entered into SPSS 10.0 statistical soft-
ware package (SPSS Inc. Chicago, IL) after the follow-up data
were recorded.
The SPSS 10.0 statistical software package (SPSS Inc.
Chicago, IL) was used for statistical analysis. Power analysis
was performed with the NCSS-PASS 2000 Statistical software
package (Number Cruncher Statistical Systems, Kaysville, UT).
For categorical variables chi-square and Fisher’s exact chi-
square tests were used. A two-tailed alpha value ≤0.05 was
accepted as statistically significant. Data were presented
descriptively as means±standard deviation when appropriate.
Odds ratios (OR) and 95% confidence intervals (95% CI) of
odds ratios of groups were calculated to evaluate the probability
of whether one drug was superior to another. The closer the odds
ratio value is to 1, the more likely it is that the analysed para-
meter is similar in both groups.
Results
Forty-seven patients with acute migraine headache admit-
ted to the ED of Uludag University School of Medicine
between October 2003 and May 2004 were randomised to
tramadol (n=23) and diclofenac (n=24) groups (Fig. 1). Of
these 47 patients, 7 were excluded from final analysis due
to protocol violations (2 in tramadol, 3 in diclofenac
groups) and patients’ decision to leave the study (1 in tra-
madol and 1 in diclofenac groups). Demographic features
and migraine characteristics of the 40 patients that com-
pleted the study are shown in Table 1.
Pain response rates and pain-free response rates at 2
and 48 h were similar for both drugs. Pain response rates
at 2 and 48 h for each trial arm are shown in Figure 2. At
Fig. 1 Randomisation of the patients
Table 1 Demographic features and migraine characteristics of the patients
Tramadol Diclofenac
Male, n (%) 6 (30) 3 (15)
Female, n (%) 14 (70) 17 (85)
Mean age±SD 37.9±13.3 37.0±11.06
Mean diagnosis duration, years±SD 6.47±4.70 6.05±3.52
Mean number of attacks per month±SD 2.70±1.17 2.40±1.23
Patients on prophylactic treatment, n (%) 3/20 (15) 3/20 (15)
Patients taken analgesic before ED, n (%) 5/20 (25) 6/20 (30)
Nausea, n (%) 18/20 (90) 15/20 (75)
Vomiting, n (%) 7/20 (35) 7/20 (35)
Photophobia, n (%) 17/20 (85) 18/20 (90)
Phonophobia, n (%) 16/20 (80) 18/20 (90)
59 patients were eligible
47 patients were randomized
Tramadol (n=23) Diclofenac (n=24)
20 patients completed
the study
12 patients were excluded, due to:
5 patients, tension type headache
3 patients, analgesic misure
1 patient, hemiplegic migraine




60 min, pain score of 9 patients in tramadol group
declined to 1 (mild) and 2 patients’ pain was relieved com-
pletely. On the other arm of the trial, at 60 min, 12 patients
pain severity decreased to mild pain and 3 patients were
pain-free. Although there was a tendency towards earlier
response to diclofenac, no statistically significant differ-
ence was detected between the two groups in terms of pain
response rates at 30, 60, 90 and 120 min. Changes in the
number of patients with (+) pain response during the study
period at 30-min intervals is shown in Figure 3.
There was no statistically significant difference
between tramadol and diclofenac groups in terms of
response rates to nausea, vomiting, photophobia and
phonophobia (Fig. 4). Rescue treatment was necessary
for 8 patients, 4 (20%) in the tramadol and 4 (20%) in
the diclofenac groups. Adverse events were observed in
a total number of 3 patients. Orthostatic hypotension
was observed in one patient in the tramadol group dur-
ing discharge who recovered spontaneously with a few
minutes rest in sitting position without need for IV flu-
Fig. 2a-d Pain response rates at 2








Fig. 3 Change in pain response rates in relation to time. *p>0.05,
OR=0.26, 95% CI=0.04–1.48. †p>0.05, OR=2.45, 95%
CI=0.64–9.39. ‡p>0.05, OR=1.33, 95% CI=0.30–5.92. §p>0.05,
OR=1.00, 95% CI=0.21–4.70
Fig. 4 Response to associated symptoms. *p>0.05, OR=1.30, 95%
CI=0.22–7.54. †p>0.05, OR=0.36, 95% CI=0.25–5.10. ‡p>0.05,
OR=0.56, 95% CI=0.12–2.60. §p>0.05, OR=0.81, 95%
CI=0.16–3.94. (■) Positive response; (■) negative response
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ids. In the diclofenac group, one patient described epi-
gastric discomfort and one patient complained of wors-
ening of nausea. Both events responded quickly to
symptomatic treatment.
At 48 h follow-up, recurrence was reported by 2 (10%)
patients in the tramadol and 3 (15%) patients in the
diclofenac groups. One patient in the diclofenac group
was re-admitted to the ED due to recurrence. Tramadol
was rated good by 11 and very good by 3 of the patients.
Diclofenac was rated good by 14 and very good by 2 of
the patients. There was no statistically significant differ-
ence between the groups in terms of global evaluation of
the drugs by patients. Fifteen (75%) patients in the tra-
madol and 16 (80%) patients in the diclofenac groups stat-
ed that they may prefer the same injection for the future
admissions.
Discussion
Acute migraine headache is a common presenting com-
plaint to the ED and there is no defined standard abortive
treatment for acute attacks. Many specific (ergots and
triptans) and non-specific treatment options are used with
varying degrees of success. Opioids are one of the most
commonly chosen agents for the ED treatment of
headaches in the USA [10]. In this prospective, ran-
domised, double-blind trial, efficacy of tramadol in
abortive treatment of acute migraine attack was evaluated
and compared with that of diclofenac sodium.
Many studies used different outcome measures defin-
ing pain relief for migraine headache. Generally, pain
response rates for different drugs studied have ranged
between 45% and 88% [2, 3, 5–9]. In our study, 2-h pain
response rate for both tramadol and diclofenac was found
to be 80% and 2-h pain-free response rates were 35% and
45% respectively. Sustained pain response at 48 h was
found to be 65% for tramadol and 60% for diclofenac.
These rates are comparable to many of the drugs studied
for the treatment of acute migraine headache and are also
clinically acceptable.
Associated symptoms generally subside with cessation
of headache pain. In our study, both drugs performed well
in relieving associated symptoms in parallel with pain.
Rescue treatment rates for different agents have been
reported to be between 11% and 33% [2, 4, 7, 8]. Rescue
treatment was necessary for a total number of 8 patients (4
in the tramadol, 4 in the diclofenac groups) in our study.
Headache recurrence rates of different treatments have
been found to be between 8% and 50% [3, 4, 8, 9]. 2/20
patients in the tramadol and 3/20 patients in the diclofenac
groups reported headache recurrence at 48-h follow-up.
Need for rescue treatment and recurrence rates of both
drugs evaluated in our study were comparable to those of
other treatment options previously studied.
Side effects were observed in 1/20 patients in the tra-
madol and 2/20 patients in the diclofenac groups. None
of the observed side effects were severe. Both drugs are
well tolerated by patients as 15 patients in the tramadol
and 16 patients in the diclofenac group stated that they
would prefer the same drug for future admissions. As
tramadol is a weak opioid, it is expected that it may
cause nausea and vomiting. Nausea or vomiting rates
after tramadol therapy have been reported between 0 and
16.5% [12–16]. In our study, we did not observe any
nausea or vomiting due to tramadol therapy. However, as
our study is small, our results may not reflect the real
side effect profile.
One of the limitations of the study is that time to par-
tial and/or complete relief was not recorded as a continu-
ous variable. This limits the value of information about
response time and consequently the length of stay at ED.
However, more than half of the patients in each group
responded well enough to be discharged at 60 min. Other
limitations were due to the setting and design of the study;
the study was designed for the treatment of a single attack
with a single dose with IM route. Therefore, the study
does not provide information about usage in multiple
migraine attacks or prophylaxis and other routes of
administration and dosing regimens.
As tramadol was not compared with placebo, because
it is not ethical to give placebo when effective treatment is
available, it is not possible to estimate how much of the
response was due to a placebo effect. The randomised
nature of our study minimises potential biases that may be
caused by the placebo effect.
A common limitation of migraine studies originates
from selection of patients, as diagnosis of migraine is
based on clinical and historical information. Although IHS
criteria are widely used in migraine studies, it was report-
ed that only 56% of patients with an ED discharge diag-
nosis of migraine met the IHS criteria [21]. The same
study reported that main deviations from the criteria were
observed in headache duration and number of prior
episodes. In our study we strictly controlled all the crite-
ria and the diagnosis was confirmed by a neurologist.
Also, although the diagnostic criteria are not different
from the first edition, we chose to use the second edition
of the IHS criteria [20] as it addressed the common prob-
lems encountered in interpretation of the criteria.
Although they are not the recommended first-line ther-
apy, opiates are commonly used for the treatment of
benign headaches at ED [10]. Tramadol, because it is a
weak opioid, is placed in the second step of the analgesic
ladder of the World Health Organization [22]. Although
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our results suggest that tramadol is an effective agent in
the treatment of acute migraine headaches, we do not
encourage its use as a first-line treatment. However, tra-
madol can be preferred in patients who are unresponsive
to first-line therapy or patients with contraindications for
NSAIDs or triptans. In conclusion, in selected patients,
tramadol 100 mg IM may be an effective and reliable
alternative treatment choice in acute migraine attacks.
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